Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis

Published:2015-04-07 Issue:5 Volume:71 Page:517-524
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Wang Zuo-Pei,Zhang Hai-Feng,Zhang Feng,Hu Bao-Li,Wei Hai-Tao,Guo Yong-Yuan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-015-1818-y.pdf

Reference35 articles.

1. Ebbers HC, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, Schellekens H (2013) Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today 18:872–879. doi: 10.1016/j.drudis.2013.05.004

2. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400. doi: 10.1038/nrd1381

3. Qi WX, Shen Z, Tang LN, Yao Y (2014) Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol 70:893–906. doi: 10.1007/s00228-014-1687-9

4. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12:356–361. doi: 10.1634/theoncologist.12-3-356

5. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713–718. doi: 10.1634/theoncologist.12-6-713

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study;Journal of Chemotherapy;2024-05-02

2. The Role of Anti-Angiogenic Agents (VEGF);Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners;2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3